- Home
- ELTX vs CGTX Comparison
ELTX vs CGTX Comparison
Compare ELTX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTX
- CGTX
- Stock Information
- Founded
- ELTX 2011
- CGTX 2007
- Country
- ELTX United States
- CGTX United States
- Employees
- ELTX N/A
- CGTX N/A
- Industry
- ELTX Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ELTX Health Care
- CGTX Health Care
- Exchange
- ELTX Nasdaq
- CGTX Nasdaq
- Market Cap
- ELTX 158.5M
- CGTX 158.8M
- IPO Year
- ELTX N/A
- CGTX 2021
- Fundamental
- Price
- ELTX $9.74
- CGTX $1.59
- Analyst Decision
- ELTX Strong Buy
- CGTX Strong Buy
- Analyst Count
- ELTX 2
- CGTX 3
- Target Price
- ELTX $11.00
- CGTX $2.83
- AVG Volume (30 Days)
- ELTX 89.8K
- CGTX 1.9M
- Earning Date
- ELTX 11-12-2025
- CGTX 11-12-2025
- Dividend Yield
- ELTX N/A
- CGTX N/A
- EPS Growth
- ELTX N/A
- CGTX N/A
- EPS
- ELTX N/A
- CGTX N/A
- Revenue
- ELTX N/A
- CGTX N/A
- Revenue This Year
- ELTX N/A
- CGTX N/A
- Revenue Next Year
- ELTX N/A
- CGTX N/A
- P/E Ratio
- ELTX N/A
- CGTX N/A
- Revenue Growth
- ELTX N/A
- CGTX N/A
- 52 Week Low
- ELTX $4.05
- CGTX $0.22
- 52 Week High
- ELTX $12.62
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- ELTX 41.51
- CGTX 45.58
- Support Level
- ELTX $9.50
- CGTX $1.59
- Resistance Level
- ELTX $10.12
- CGTX $1.78
- Average True Range (ATR)
- ELTX 0.52
- CGTX 0.15
- MACD
- ELTX -0.05
- CGTX -0.02
- Stochastic Oscillator
- ELTX 28.00
- CGTX 4.17
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.